Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Code Biotherapeutics Inc.

Headquarters: Hatfield, PA, United States of America
Year Founded: 2020
Status: Private
BioCentury | Oct 22, 2024
Management Tracks

Ray Jupp named CSO at ViaNautis

Plus: Pellegrini joins Kaia and an update from AAVantgarde
BioCentury | Jul 30, 2024
Product Development

Venturing beyond AAVs and LNPs to deliver therapeutic cargo

Dozens of companies aim to avoid immunogenicity and improve tissue-specificity
BioCentury | Nov 16, 2022
Management Tracks

Bungay becomes CEO at Imophoron, Garzoni transitions to CSO

Plus: Tracy named CTO at Code, and updates from ConcertAI, Lucy, Trevi and more
BioCentury | Sep 29, 2022
Management Tracks

Kevin Bunker promoted to CSO at Zentalis

Plus Fonck becomes partner at Pureos, and updates from 4D Molecular, Gandeeva, Code and more
BioCentury | Sep 21, 2022
Product Development

How venture philanthropy is driving modality innovation for DMD

Targeted antisense and non-viral gene therapies top CureDuchenne’s technology priority list
BioCentury | Jun 7, 2022
Finance

Code financing puts it in top 10 for 2022 series A rounds

Non-viral gene therapy play raises $75M in deal led by Northpond Ventures
BioCentury | Jun 7, 2022
Data Byte

Top series A rounds of U.S. biotechs year to date

The year has seen 11 U.S. therapeutics developers raise series As of $75M or more, mostly funding new modality platform plays
BioCentury | Feb 23, 2022
Product Development

Feb. 22 Quick Takes: Enhertu meets mark in breast cancer subgroup

Plus updates from BeiGene, Takeda, Code, Kiniksa, Hangzhou, Homology and more
BioCentury | Feb 2, 2022
Emerging Company Profile

BioCentury’s 2021 class of emerging companies

An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
BioCentury | Dec 4, 2021
Management Tracks

Aubuchon becomes CCO at AbCellera

Plus: Albireo, Fore, Code, SomaLogic and more
Items per page:
1 - 10 of 13